Brief: Poxel Announces Positive Topline Results For Imeglimin Phase 3 Trial (TIMES 3 36-Week)

Poxel SA

26/11/2019 06:02

Nov 26 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL ANNOUNCES POSITIVE TOPLINE RESULTS FOR IMEGLIMIN
PHASE 3
TRIAL (TIMES 3 36-WEEK) FOR THE TREATMENT OF TYPE 2 DIABETES IN
JAPAN
    * IMEGLIMIN IN COMBINATION WITH INSULIN WAS OBSERVED TO
DEMONSTRATE CONSISTENT AND SUSTAINED EFFICACY IN THE TIMES 3
36-WEEK, OPEN-LABEL EXTENSION PERIOD
    * PHASE 3 RESULTS FROM THE TIMES 2 TRIAL ARE ANTICIPATED
AROUND
THE END OF 2019
    * IMEGLIMIN JAPANESE NEW DRUG APPLICATION (JNDA) TARGETED
FOR 2020
    * IMEGLIMIN IN COMBINATION WITH INSULIN WAS OBSERVED TO SHOW
A
FAVORABLE SAFETY AND TOLERABILITY PROFILE THROUGHOUT THE 52
WEEKS OF TREATMENT IN TIMES 3

Source text for Eikon:  ID:nBw484DcHa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))